High blood pressure variability (BPV) has been associated with increased cardiovascular (CV) risk. The effect of dietary salt and renin-angiotensin-aldosterone system (RAAS) activity on short-term BPV in type 2 diabetes mellitus (T2DM) is not well characterised. We aimed to determine the effect of dietary salt (sodium chloride, NaCl) supplementation on 24-h mean arterial BPV (24hBPV) during angiotensin II receptor blocker (telmisartan) use and to evaluate the effects of age, sex, plasma renin activity (PRA) and serum aldosterone on 24hBPV. In a randomised, double-blind, crossover study, patients with T2DM (n = 28), treated with telmisartan received NaCl (100 mmol/24 h) or placebo capsules during 2 weeks of telmisartan. Following a 6-week washout, the protocol was repeated in reverse. 24hBPV was evaluated as a co-efficient of variation [CV (%) = mean/standard deviation] × 100). Twenty-four hour urinary sodium excretion, ambulatory BP and biochemical tests were performed at each phase. Results were analysed using a linear mixed model to generate predicted values for 24hBPV. Predicted 24hBPV was higher with telmisartan vs baseline (p = 0.01), with a trend towards reduced 24hBPV with salt (p = 0.052). Predicted 24hBPV was lower in females (p = 0.017), increasing age (p = 0.001) and increasing PRA (p = 0.011). In patients with T2DM, predicted 24hBPV increased from baseline with telmisartan, but there was no additional increase in predicted 24hBPV with salt supplementation. This suggests that in the short-term, salt supplementation has no apparent deleterious effects on 24hBPV. Long-term studies are required to evaluate the effect of 24hBPV on CV outcomes in patients with T2DM.
Introduction
Hypertension is a major risk factor for cardiovascular (CV) mortality and CV events are the leading cause of death in patients with diabetes [1] . Blood pressure continually oscillates, giving rise to blood pressure variability (BPV) [2] .
In clinical studies, BPV is conceptualised in the short-term (i.e. within 24 h), and in the long-term (i.e. day to day or visit to visit) [2] . Factors such as autonomic nervous system activity, dietary sodium and potassium intake and humoral mediators including the renin-angiotensin-aldosterone system (RAAS) all influence short-term BPV [2] . Elevated long-term BPV is associated with increased CV risk and mortality in the general population [3, 4] and with accelerated progression of microvascular complications in patients with diabetes [5, 6] . In contrast, the relationship between short-term BPV and CV outcomes is less clear, although a meta-analysis reported an association between elevated short-term BPV and increased stroke risk [7] . As short-term BPV may be an independent modifiable risk factor for CV disease, with clinical management implications, additional studies are necessary to characterise the relationship between short-term BPV and CV outcomes.
Observational studies in the general population have explored the effects of age [8] , sex [9] and antihypertensive medication use [10] on short-term BPV. We have previously shown that short-term dietary salt supplementation during telmisartan use was associated with lower plasma renin activity (PRA) compared with telmisartan alone [11] . However, the effects of RAAS blockade and dietary salt intake on short-term BPV in patients with type 2 diabetes have not been previously described.
The current exploratory analysis was carried out to evaluate the effect of salt (sodium chloride, NaCl) supplementation on predicted 24-h mean arterial BPV (24hBPV) during angiotensin II receptor blocker (ARB) use (telmisartan) and to determine the effects of age, sex, PRA and serum aldosterone on 24hBPV in a randomised doubleblinded crossover study.
Methods
In a randomised, double-blind, placebo-controlled crossover study ( Fig. 1 ), 28 participants were recruited from outpatient clinics at Austin Health, a tertiary referral centre in Melbourne, Australia. Details of the study design have previously been reported [12] . All participants underwent a 6-week washout where usual anti-hypertensives were replaced with agents that have no effect on RAAS including verapamil, prazosin, methyldopa or hydralazine, to achieve BP < 160/95 mmHg. Randomisation was carried out using computer software by Austin Health pharmacy in a doubleblinded manner. All patients were treated with telmisartan 40 mg for 4 weeks and on the basis of randomisation, received either sodium chloride (100 mmol/24 h) or placebo capsules for the final 2 weeks of telmisartan use. This was followed by a 6-week washout, where anti-hypertensives without effects on the RAAS were used, after which the protocol was repeated in reverse.
Inclusion criteria were the presence of type 2 diabetes, hypertension with blood pressure >140/90 mmHg and albumin excretion rate between 10 and 200 µg/min (determined by the median of three consecutively collected 24-h urine samples in 12 months). Exclusion criteria were albumin excretion ratio > 200 µg/min, serum creatinine > 200 µM, serum potassium > 5.0 mM, haemoglobin A 1c (HbA 1c ) > 10.0% and any cases of major systemic illness. Major systemic illnesses included conditions such as sepsis, end-stage organ failure involving any system (such as liver failure, end-stage renal disease and cardiac failure), current malignancy or any conditions that in the opinion of the investigator would make participation not in the best interest of the participant. Ethics approval was obtained from Austin Health Human Research Ethics Committee (Australian Clinical Trials Registry, Registration number ACTRN012606000128594) prior to study commencement. Participants provided informed written consent prior to study enrolment.
Sodium chloride and placebo capsules (containing lactose) were produced at a local compounding pharmacy (Thompson's Pharmacy, Eltham, Australia). Capsules were taken at breakfast, lunch and dinner to ensure that a total of 100 mmol sodium chloride was ingested every 24 h in addition to the individual's usual diet.
Twenty-four hour ambulatory blood pressure (24hABPM) was measured using oscillometric methods, blood pressure measurements were performed at 30-min intervals between 0600 and 2400 h and at hourly intervals between 0000 and 0600 h, an average of 28 blood pressure measurements were made between 0600 and 2400 and ten blood pressure measurements were made between 2400 and 0600. Twenty-four hour urinary sodium excretion (24hUNa), 24hABPM and biochemical tests were performed following each study phase. Blood was collected after participants had been seated for at least 15 min following an overnight fast. PRA was measured using Gam-maCoat PRA radio-immunoassay (Diasorin Inc, Stillwater, MN, USA) with a co-efficient of variation (CV) of 16% at levels between 2 and 5.5 μg/l/h. Serum aldosterone was measured using Count-A-Coat radio-immunoassay (Siemens, Los Angeles, CA, USA), with CV of 10% at 110 pmol/l and 13% at 1499 pmol/l.
Endpoints
The current study was carried out as an exploratory subanalysis to evaluate the effect of telmisartan use and NaCl supplementation on predicted 24hBPV and to characterise the effects of age, sex, PRA and serum aldosterone on 24hBPV. The co-primary endpoints of the original study were to evaluate the effect of angiotensin II receptor blockade and short-term dietary NaCl supplementation on albuminuria and blood pressure in patients with type 2 diabetes mellitus (T2DM) [12, 13] .
Statistical analysis
The sample size in the primary study was calculated to detect difference in BP response of 1 SD with power 90% and α 5%. On the basis of previous studies [14] , where mean difference in ambulatory BP in ten subjects, taken weeks apart, was 2 ± 5.5 mmHg, it was calculated that 15 subjects were required for adequate power in this crossover design. 24hBPV was evaluated as a co-efficient of variation, using the following calculation: (CV (%) = [mean BP/standard deviation BP] × 100%) [2, 15] , where mean was calculated from the mean value of all BP readings from 24hABPM, therefore adjusting for MAP. The current study takes both daytime and nighttime MAP readings into account when evaluating 24hBPV. Daytime was taken as 0600-2200 h, and nighttime was 2200-0600 h.
The effect of salt supplementation, age, sex, ARB use, PRA and serum aldosterone on BPV were analysed and modelled with a linear mixed model (LMM). With respect to inference, the primary endpoint was the "predicted" 24hBPV, as analysis of each participant's trajectory with LMM gives rise to a "predicted" 24hBPV based on the statistical model; this is a currently recommended method of analysis of clinical trial data for continuous variables with repeated measures over time [16] . Analysis was adjusted for covariates of age, sex and GFR and modelling the residual errors as a Gaussian process over time. Use of antihypertensives in addition to telmisartan was not specifically adjusted for due to small number of participants in the trial. Statistical analysis was carried out using Stata V14.1 (College Station, TX, USA). Skewed variables (PRA and serum aldosterone) were log 10 transformed prior to statistical analysis. Predicted values from the LMM were estimated using the "margins" command in Stata statistical software [17] . As the measurements across BP components were consistent in our current study, we have presented CV of mean arterial BP. Data for systolic and diastolic BPV are also presented.
Results

Participants
Thirty-two participants were recruited, 28 participants completed the study [12] . One participant experienced significant gastrointestinal side effects due to NaCl capsules, three participants did not complete all study requirements. Baseline participant characteristics are outlined in Table 1 . Additional systolic and diastolic BP variables during different study phases are outlined in Table 2 .
Angiotensin II receptor blockade and salt supplementation
There was no difference in mean 24hBPV between telmisartan and placebo vs telmisartan and salt supplementation (p = 0.10). However, when compared with baseline, telmisartan and placebo was associated with increased predicted 24hBPV. Predicted mean 24hBPV with telmisartan and placebo was 11.7% (95% CI: 10.9-12.5%). Compared with predicted baseline, telmisartan and placebo led to an increase in predicted mean 24hBPV of 2.1 ± 0.7% (p = 0.002) ( Table 3) .
Telmisartan in conjunction with salt was associated with a trend towards reduced predicted 24hBPV compared with telmisartan and placebo. Predicted mean 24hBPV with telmisartan and salt was 10.6% (95% CI: 9.8-11.4%). This increase in predicted mean 24hBPV of 0.9 ± 0.6% from baseline was not significant (p = 0.15) ( Table 3) .
Of note, there was no significant differences in 24-h urinary potassium excretion during the different phases, suggesting that participants diet otherwise remained the similar throughout the study phases. Effects on predicted systolic and diastolic BPV are outlined in Table 4 .
PRA and serum aldosterone
Using our linear mixed model, we evaluated if PRA and serum aldosterone predicted 24hBPV. At baseline and during both stages of intervention, we found that increasing PRA was associated with a small, yet significantly lower predicted mean 24hBPV by −1.5% (95% CI: −2.7 to −0.4%) for every unit log 10 PRA increase (p = 0.011). Increasing serum aldosterone had no effect on predicted mean 24hBPV (Table 3 ).
Age and sex
Each year increase in age was associated with lower predicted mean 24hBPV by -2.0% (95% CI: −3.1 to 0.9%, p = 0.001). Predicted mean 24hBPV was 5.4 ± 2.3% (p = 0.017) higher with male participants than females ( Table 3 ). As the relationship between age and blood pressure parameters is not linear in real life, quadratic of age was also evaluated. Sex and the quadratic of age were jointly significant predictors for mean 24hBPV (p = 0.048), suggesting age predicts for mean 24hBPV in a non-linear manner and from age 65 years onwards, there was a trend towards increasing 24hBPV in both males and females (Fig. 2 ).
Discussion
Key findings
The key finding of the current analysis was that in hypertensive patients with type 2 diabetes and microalbuminuria, short-term telmisartan was associated with a small, but significant increase in predicted 24hBPV. This increase was attenuated with dietary salt supplementation. Female sex, older age and higher PRA were factors associated with lower predicted 24hBPV in patients with type 2 diabetes.
Relationship to previous studies 24hBPV and antihypertensive medications
Antihypertensive medications act through a variety of mechanisms, with varying BPV effects. Telmisartan use was associated with increased predicted 24hBPV, a finding that is consistent with reports in the literature [10] . ARB use increases PRA and angiotensin II [18] , leading to arterial stiffness and peripheral vascular distention [19] . Compared with other antihypertensive medication classes, diuretics and dihydropyridine calcium channel blockers (CCB) consistently demonstrate short-term BPV lowering effects both within the general population and in patients with diabetes [20] [21] [22] . Short-term BPV is highly dependent on sympathovagal balance, baroreflex activity and arterial stiffness [19] . Indeed, renal sympathetic denervation leads to significant short-term BPV reductions, independent of absolute BP lowering [23] . In the current study, telmisartan use reduced mean arterial BP, but increased predicted 24hBPV, highlighting the independent relationship between absolute BP and BPV per se.
24hBPV and dietary salt supplementation
Despite the interaction between salt intake and blood pressure, few studies have evaluated the effect of dietary salt supplementation on short-term BPV in patients with type 2 diabetes. Compared with telmisartan and placebo, telmisartan and salt had no effect on predicted 24hBPV. Observational studies have demonstrated a "J" shaped association between dietary salt intake and mortality, such that both excessively high and low salt intake are associated with increased mortality risk [24] . However, there is conflicting evidence regarding the effect of dietary salt intake Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure. . . on short-term BPV. In 80 healthy, normotensive subjects placed firstly on low NaCl diet (20 mmol/day for 7 days), followed by a high NaCl diet (300 mmol/day for 7 days), there was no difference in short-term BPV identified [25] and in ten hypertensive, Japanese patients with type 2 diabetes, dietary salt restriction to less than 6 g per day, was not associated with any reductions in 24-h diurnal BPV (p = 0.959) [26] . Taken together with the current study, shortterm increases in dietary salt intake have not been found to be associated with deleterious effects on short-term BPV in patients with type 2 diabetes. Effects of long-term salt supplementation on short-term BPV cannot be extrapolated from current study findings. Dietary salt restriction augments sympathetic nervous system activity and reduces baroreflex activity [27] , which may provide a mechanistic explanation as to why dietary salt supplementation leads to a trend to reduced 24hBPV during telmisartan use.
24hBPV and the RAAS
The key physiological role of renin is to induce glomerular efferent arteriolar constriction via angiotensin II and increase the blood volume during hypovolaemia [28] . Long-term ARB use is associated with increased PRA, angiotensin I and angiotensin II [18] . In the current study, telmisartan use was associated with increased PRA and predicted 24hBPV. Yet, when analysed in the multivariate LMM model, predicted 24hBPV was lower with increasing PRA. The relationship between PRA and short-term BPV is not clear. A recent Japanese study evaluating 24hBPV in different hypertension aetiologies, (essential vs renovascular vs primary hyperaldosteronism) found no difference in 24hBPV despite significantly increased PRA in the reno-vascular hypertension group [29] . However, in 61 healthy male subjects, increasing PRA was inversely related to short-term BPV [30] , a finding that is consistent with the current study. Radio-immunoassay PRA measurements incorporate renin, open pro-renin and angiotensin I concentration [31] . As ARBs act at sites distal to angiotensin I release, active PRA may be overestimated by up to 90% [31] . This may also reflect the extent of RAAS blockade, 40 mg of telmisartan was chosen as this is the standard starting dose. Pharmacodynamic studies have shown that 80 mg of telmisartan blocks angiotensin II responses by 90% at its peak and at 40% over 24 h [32] . The increase in 24hBPV following telmisartan administration may therefore reflect incomplete RAAS blockade. If indeed there has been incomplete RAAS blockade with telmisartan at current doses, this may also account for 24hBPV attenuation with salt supplementation during telmisartan as salt repletion lowers PRA making complete RAAS more achievable. Finally, it needs to be noted that angiotensin II concentration has not been measured and may in part explain the paradoxical findings of the effects of telmisartan vs PRA levels on predicted 24hBPV. These factors need to be taken into consideration when evaluating current study findings.
24hBPV and age
Within the general population, short-term BPV increases with increasing age [33] . In the Ohasama study [33] , increasing age was associated with increased short-term BPV independent of BP. In the current study, predicted 24hBPV decreased with increasing age. However, when modelled based on sex and the quadrative of age, increasing age from 62 years in females and 70 years in males was associated with increasing 24hBPV. Given the study's pragmatic setting, it would be reasonable to expect the relationship between age and 24hBPV is not a simple linear one.
24hBPV and sex
Observational studies in both the general population and patients with diabetes have shown a tendency for higher short-term BPV in females compared with males [22, 33] . In our group, male sex was associated with a small but significant increase in mean predicted 24hBPV (5.4 ± 2.3% [p = 0.017]), but by age 64 years females had higher predicted 24hBPV compared with males ( Fig. 2) . Oestrogen exposure is associated with CCB-like effects on the smooth muscle of arterial walls and studies comparing short-term BPV in pre and post-menopausal women have demonstrated higher short-term BPV in post-menopausal women [34] .
Strengths and limitations
The strengths in the current study lie in its randomized, double-blinded, placebo-controlled design. Moreover, we used 24hUNa to evaluate dietary salt intake to ensure all salt supplementation was being taken. Renal sodium excretion accounts for 90% of total sodium excretion, as such 24hUNa is the most accurate estimate of dietary salt intake [35] . Many variations for the calculation of BPV exist, the accuracy of BPV measured with intermittent ambulatory blood pressure monitoring where BP is recorded at 15-60 min intervals is comparable with beat-to-beat blood pressure monitoring [36] . In addition, 24hBPV was assessed as the standard deviation of mean 24-h BPV. This is the most commonly utilized method for assessing BPV and is used in population studies evaluating the relationship between 24hBPV and CV outcomes [2, 19] . We have evaluated both daytime and nighttime BPV and taken the full 24 h of BP readings in our final assessment, accounting for day-night blood pressure fluctuations.
We recognise the limitations in the current study. Given the interplay between sympathetic nervous system activity and 24hBPV, study strength would have been improved with measurement of other parameters of autonomic nervous system activity; in particular heart rate variability, baroreflex activity and the effect of long-term BPV fluctuations on 24hBPV. Evaluation of RAAS system including serum angiotensin II and potential renal RAAS activity should be considered in future definitive studies. Moreover, we recognize the small number of study subjects and the limited duration of intervention of only 4 weeks for telmisartan and 2 weeks for additional salt supplementation.
Conclusion
In summary, we demonstrated that, telmisartan use was associated with a small, but significant increase in predicted 24hBPV in hypertensive patients with type 2 diabetes and microalbuminuria. This increase in predicted 24hBPV was attenuated with dietary salt supplementation. Female sex, older age and higher PRA were factors associated with lower predicted 24hBPV in this patient group. Dietary salt supplementation was not associated with any further deleterious effect on short-term BPV in patients with type 2 diabetes. The above may be due to the effect of dietary salt supplementation on autonomic nervous system activity, as dietary salt restriction has been associated with increased sympathetic nervous system activity.
The relationship between short-term BPV and CV risk remains to be fully defined. However, CV disease continues to be one of the leading causes of mortality worldwide. Despite improvements in hypertension management, shortterm BPV have been found to be important and potentially independent risk factors for the development of CV disease [2, 15] . A better understanding of the modifiable factors that contribute BPV fluctuations represents important targets that may be utilised to further attenuate population CV risk, particularly in relation to dietary sodium intake within this setting. Although, the findings from this study are hypothesis generating, they highlight the need for further, definitive studies evaluating the effect of raised 24hBPV on CV outcomes in patients with type 2 diabetes. The study also provides novel insight into both modifiable and nonmodifiable targets for lowering 24hBPV should this become a further focus in clinical care.
Summary Table
What is known about the topic • Short-term BPV is influenced by a range of factors including autonomic nervous system activity, dietary factors and humoral mediators such as renin-angiotensin-aldosterone system.
• Raised long-term BPV is associated with increased CV risk and mortality in the general population and with accelerated progression of microvascular complications in individuals with diabetes.
• Raised short-term BPV may be an independent modifiable risk factor for CV disease.
What this study adds In this exploratory analysis in patients with T2DM:
• Telmisartan use was associated with a small, but significant increase in predicted short-term BPV. This increase in short-term BPV was attenuated with dietary salt supplementation.
• Short-term dietary salt supplementation was not associated with any deleterious effect on short-term BPV.
• Female sex, older age and higher PRA were factors associated with lower predicted short-term BPV.
